播放中国国产国语纯一级黄片免费看, 大鸡吧快来啊阿啊阿啊黄片在线播放, 中文精品日韩网站在线观看视频免费, 别揉我奶头~嗯~啊~一区二区三区,AV无码播放一级毛片免费古装,亚洲春色一区二区三区,91大神极品,美国一级大黄一片免费下载,午夜爽爽爽男女免费观看软件

Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Flavoxate hydrochloride, also known as ChEBI, is the hydrochloride salt of flavoxate. It is a crystalline solid that possesses unique chemical properties, making it a valuable compound in various applications.

3717-88-2

Post Buying Request

3717-88-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

3717-88-2 Usage

Uses

Used in Pharmaceutical Industry:
Flavoxate hydrochloride is used as an antispasmodic agent for the treatment of urinary incontinence. It helps to relieve muscle spasms in the urinary tract, providing relief from the symptoms of incontinence.
Used in Medical Applications:
Flavoxate hydrochloride is used as a phosphodiesterase inhibitor, which plays a role in the regulation of smooth muscle tone. By inhibiting phosphodiesterase, it can help to relax smooth muscles, particularly in the urinary tract, providing relief from urinary disorders and improving overall bladder function.

Therapeutic Function

Spasmolytic

Veterinary Drugs and Treatments

Flovoxate may be considered for treating dogs with detrusor hyperspasticity (hyperactive bladder, urge incontinence).

Check Digit Verification of cas no

The CAS Registry Mumber 3717-88-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,7,1 and 7 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 3717-88:
(6*3)+(5*7)+(4*1)+(3*7)+(2*8)+(1*8)=102
102 % 10 = 2
So 3717-88-2 is a valid CAS Registry Number.
InChI:InChI=1/C24H25NO4.ClH/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25;/h2,4-5,8-12H,3,6-7,13-16H2,1H3;1H

3717-88-2 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (F0717)  Flavoxate Hydrochloride  >98.0%(HPLC)(T)

  • 3717-88-2

  • 5g

  • 450.00CNY

  • Detail
  • TCI America

  • (F0717)  Flavoxate Hydrochloride  >98.0%(HPLC)(T)

  • 3717-88-2

  • 25g

  • 990.00CNY

  • Detail
  • Sigma-Aldrich

  • (Y0000736)  Flavoxate hydrochloride  European Pharmacopoeia (EP) Reference Standard

  • 3717-88-2

  • Y0000736

  • 1,880.19CNY

  • Detail
  • USP

  • (1270708)  Flavoxate hydrochloride  United States Pharmacopeia (USP) Reference Standard

  • 3717-88-2

  • 1270708-200MG

  • 4,662.45CNY

  • Detail
  • Sigma

  • (F8304)  Flavoxate hydrochloride  ≥98% (HPLC), solid

  • 3717-88-2

  • F8304-10MG

  • 1,730.43CNY

  • Detail
  • Sigma

  • (F8304)  Flavoxate hydrochloride  ≥98% (HPLC), solid

  • 3717-88-2

  • F8304-50MG

  • 6,633.90CNY

  • Detail

3717-88-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name flavoxate hydrochloride

1.2 Other means of identification

Product number -
Other names Flavoxate Hydrochloride

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:3717-88-2 SDS

3717-88-2Relevant articles and documents

METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS

-

, (2021/03/13)

In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.

Halo-containing 3-methylflavone-8-carboxylic acid derivatives

-

, (2008/06/13)

This invention relates to derivatives of 3-methylflavone-8-carboxylic acid represented by the formula (1) STR1 wherein R represents a hydrogen atom, a lower alkyl group or a group STR2 (wherein R1 and R2 represent a lower alkyl group or R1 and R2, when taken together with the nitrogen atom to which they are attached, may form a heterocyclic ring with or without an intervening hetero atom, and n is an integer of 1 to 4), and X represents a halogen atom, which are useful as intermediates. This invention also relates to processes for preparing the same.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 3717-88-2